Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIRx Med

Date Submitted: Sep 9, 2021
Date Accepted: Sep 9, 2021

The final, peer-reviewed published version of this preprint can be found here:

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

Jarrett MP, Licht WB, Bock K, Brown Z, Hirsch JS, Coppa K, Brar R, Bello S, Nash IS

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

JMIRx Med 2021;2(3):e33496

DOI: 10.2196/33496

PMCID: 10414264

Authors' Responses to Peer Review of "Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study" (ms#29638)

  • Mark Paul Jarrett; 
  • Warren B Licht; 
  • Kevin Bock; 
  • Zenobia Brown; 
  • Jamie S Hirsch; 
  • Kevin Coppa; 
  • Rajdeep Brar; 
  • Steve Bello; 
  • Ira S Nash

ABSTRACT

These are author responses to peer review associated with ms#29638


 Citation

Please cite as:

Jarrett MP, Licht WB, Bock K, Brown Z, Hirsch JS, Coppa K, Brar R, Bello S, Nash IS

Authors' Response to Peer Reviews of “Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study”

JMIRx Med 2021;2(3):e33496

DOI: 10.2196/33496

PMCID: 10414264

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.